Zhang X, Li H, Wang Y, Zhao H, Wang Z, Chan F
Cell Death Dis. 2024; 15(3):234.
PMID: 38531859
PMC: 10965960.
DOI: 10.1038/s41419-024-06621-w.
Garcia-Yague A, Cuadrado A
Int J Mol Sci. 2023; 24(15).
PMID: 37569656
PMC: 10419244.
DOI: 10.3390/ijms241512280.
Ou D, Wu Y
BMC Cancer. 2021; 21(1):1327.
PMID: 34903206
PMC: 8667451.
DOI: 10.1186/s12885-021-09058-y.
Safe S, Karki K
Mol Cancer Res. 2020; 19(2):180-191.
PMID: 33106376
PMC: 7864866.
DOI: 10.1158/1541-7786.MCR-20-0707.
Wan P, Siu M, Leung T, Mo X, Chan K, Ngan H
Cancers (Basel). 2020; 12(10).
PMID: 33086676
PMC: 7590204.
DOI: 10.3390/cancers12103044.
Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas.
Karki K, Li X, Jin U, Mohankumar K, Zarei M, Michelhaugh S
J Neurooncol. 2019; 146(1):25-39.
PMID: 31754919
PMC: 7054911.
DOI: 10.1007/s11060-019-03349-y.
Structural basis of binding of homodimers of the nuclear receptor NR4A2 to selective Nur-responsive DNA elements.
Jiang L, Dai S, Li J, Liang X, Qu L, Chen X
J Biol Chem. 2019; 294(51):19795-19803.
PMID: 31723028
PMC: 6926456.
DOI: 10.1074/jbc.RA119.010730.
Function of Nr4a Orphan Nuclear Receptors in Proliferation, Apoptosis and Fuel Utilization Across Tissues.
Herring J, Elison W, Tessem J
Cells. 2019; 8(11).
PMID: 31683815
PMC: 6912296.
DOI: 10.3390/cells8111373.
Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.
Jakaria M, Haque M, Cho D, Azam S, Kim I, Choi D
Mol Neurobiol. 2019; 56(8):5799-5814.
PMID: 30684217
DOI: 10.1007/s12035-019-1487-4.
Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.
Dhiman V, Bolt M, White K
Nat Rev Genet. 2017; 19(3):160-174.
PMID: 29279606
DOI: 10.1038/nrg.2017.102.
Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.
Komiya T, Yamamoto S, Roy A, McDonald P, Perez R
Transl Lung Cancer Res. 2017; 6(5):600-610.
PMID: 29114475
PMC: 5653521.
DOI: 10.21037/tlcr.2017.07.02.
Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.
Sun Z, Ju Y, Han F, Sun X, Wang F
J Clin Lab Anal. 2017; 32(3).
PMID: 28605139
PMC: 6816827.
DOI: 10.1002/jcla.22277.
Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2.
Zhu B, Sun L, Luo W, Li M, Coy D, Yu L
Oncotarget. 2017; 8(14):23289-23302.
PMID: 28423575
PMC: 5410304.
DOI: 10.18632/oncotarget.15576.
Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma.
Ji L, Gong C, Ge L, Song L, Chen F, Jin C
Exp Ther Med. 2017; 13(2):551-559.
PMID: 28352330
PMC: 5348705.
DOI: 10.3892/etm.2016.3968.
Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
Wang J, Yang Z, Chen H, Li H, Chen L, Zhu Z
BMC Cancer. 2016; 16:257.
PMID: 27036119
PMC: 4815267.
DOI: 10.1186/s12885-016-2291-4.
Orphan nuclear receptor NR4A2 inhibits hepatic stellate cell proliferation through MAPK pathway in liver fibrosis.
Chen P, Li J, Huo Y, Lu J, Wan L, Li B
PeerJ. 2015; 3:e1518.
PMID: 26713258
PMC: 4690364.
DOI: 10.7717/peerj.1518.
Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer.
Guo J, Zu G, Zhou T, Xing J, Wang Z
Clin Transl Oncol. 2015; 17(10):788-94.
PMID: 26022133
DOI: 10.1007/s12094-015-1305-z.
Nuclear receptor 4A (NR4A) family - orphans no more.
Safe S, Jin U, Morpurgo B, Abudayyeh A, Singh M, Tjalkens R
J Steroid Biochem Mol Biol. 2015; 157:48-60.
PMID: 25917081
PMC: 4618773.
DOI: 10.1016/j.jsbmb.2015.04.016.
Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J, Srivastava G, Matta A, MacMillan C, Ralhan R, Walfish P
PLoS One. 2015; 10(2):e0107586.
PMID: 25695234
PMC: 4335027.
DOI: 10.1371/journal.pone.0107586.
Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.
Safe S, Jin U, Hedrick E, Reeder A, Lee S
Mol Endocrinol. 2013; 28(2):157-72.
PMID: 24295738
PMC: 3896638.
DOI: 10.1210/me.2013-1291.